• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line.双皮质醇激酶 1 在人结肠癌细胞系中表现出癌症干细胞样特征。
Chin J Cancer Res. 2013 Apr;25(2):134-42. doi: 10.3978/j.issn.1000-9604.2013.03.02.
2
Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.靶向结肠癌干细胞的新型双皮质素样激酶 1 抗体功能化叶酸偶联橙皮苷包封壳聚糖纳米粒
Colloids Surf B Biointerfaces. 2022 Sep;217:112612. doi: 10.1016/j.colsurfb.2022.112612. Epub 2022 Jun 7.
3
Sox9, Hopx, and survivin and tuft cell marker DCLK1 expression in normal canine intestine and in intestinal adenoma and adenocarcinoma.Sox9、Hopx、存活素以及簇状细胞标志物DCLK1在正常犬肠道、肠道腺瘤和腺癌中的表达。
Vet Pathol. 2022 May;59(3):415-426. doi: 10.1177/03009858221079666. Epub 2022 Feb 26.
4
Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.DCLK1 的可变剪接异构体标记癌症干细胞,促进自我更新和耐药性,并可作为靶点抑制肾癌的肿瘤发生。
Int J Cancer. 2018 Sep 1;143(5):1162-1175. doi: 10.1002/ijc.31400. Epub 2018 Apr 16.
5
Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.双皮质素样激酶1(DCLK1)调节B细胞特异性莫洛尼鼠白血病病毒插入位点1(Bmi-1),并与胰腺癌的转移和预后相关。
Cell Physiol Biochem. 2018;51(1):262-277. doi: 10.1159/000495228. Epub 2018 Nov 19.
6
Doublecortin-like kinase 1 compromises DNA repair and induces chromosomal instability.双皮质素样激酶1损害DNA修复并诱导染色体不稳定。
Biochem Biophys Rep. 2018 Oct 30;16:130-137. doi: 10.1016/j.bbrep.2018.10.014. eCollection 2018 Dec.
7
Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.双皮质素样激酶1阳性的小肠上皮簇细胞表现出静止和自我更新的特征。
Oncotarget. 2015 Oct 13;6(31):30876-86. doi: 10.18632/oncotarget.5129.
8
Long-lived intestinal tuft cells serve as colon cancer-initiating cells.长寿的肠簇细胞作为结肠癌起始细胞。
J Clin Invest. 2014 Mar;124(3):1283-95. doi: 10.1172/JCI73434.
9
A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.一种针对癌症干细胞生物标志物DCLK1-S的新型抗体,可能有助于评估结肠镜筛查后的结肠癌风险。
Lab Invest. 2017 Oct;97(10):1245-1261. doi: 10.1038/labinvest.2017.40. Epub 2017 Apr 17.
10
Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.簇绒细胞和癌症干细胞标志物DCLK1:增强肿瘤微环境中抗肿瘤免疫的新靶点。
Cancers (Basel). 2020 Dec 17;12(12):3801. doi: 10.3390/cancers12123801.

引用本文的文献

1
Targeting the PI3K/AKT/mTOR pathway offer a promising therapeutic strategy for cholangiocarcinoma patients with high doublecortin-like kinase 1 expression.针对双皮质素样激酶 1 高表达的胆管癌患者,靶向 PI3K/AKT/mTOR 通路提供了一种有前景的治疗策略。
J Cancer Res Clin Oncol. 2024 Jul 9;150(7):342. doi: 10.1007/s00432-024-05875-3.
2
Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies.癌症干细胞的当前认识:胃肠道恶性肿瘤中的免疫逃逸与靶向免疫治疗
Front Oncol. 2023 Feb 23;13:1114621. doi: 10.3389/fonc.2023.1114621. eCollection 2023.
3
Pleiotropic effects of DCLK1 in cancer and cancer stem cells.DCLK1在癌症和癌症干细胞中的多效性作用。
Front Mol Biosci. 2022 Sep 26;9:965730. doi: 10.3389/fmolb.2022.965730. eCollection 2022.
4
Oncogenic functions and clinical significances of DCLK1 isoforms in colorectal cancer: a systematic review and meta-analysis.DCLK1 亚型在结直肠癌中的致癌功能及临床意义:一项系统综述和荟萃分析
Cancer Cell Int. 2022 Jun 18;22(1):217. doi: 10.1186/s12935-022-02632-9.
5
Autoregulatory control of microtubule binding in doublecortin-like kinase 1.双皮质素样激酶 1 中微管结合的自动调节控制。
Elife. 2021 Jul 26;10:e60126. doi: 10.7554/eLife.60126.
6
Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.簇绒细胞和癌症干细胞标志物DCLK1:增强肿瘤微环境中抗肿瘤免疫的新靶点。
Cancers (Basel). 2020 Dec 17;12(12):3801. doi: 10.3390/cancers12123801.
7
Doublecotin-Like Kinase 1 Increases Chemoresistance of Colorectal Cancer Cells through the Anti-Apoptosis Pathway.双皮质素样激酶1通过抗凋亡途径增加结肠癌细胞的化疗耐药性。
J Stem Cell Res Ther. 2019;9(3). doi: 10.4172/2157-7633.1000447. Epub 2019 May 3.
8
Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer.利用 miR-15b 靶向 DCLK1 增强结直肠癌对化疗/放疗的敏感性。
Stem Cell Reports. 2018 Dec 11;11(6):1506-1522. doi: 10.1016/j.stemcr.2018.10.015. Epub 2018 Nov 15.
9
Dclk1-expressing tuft cells: critical modulators of the intestinal niche?表达双皮质素样激酶1的簇状细胞:肠道生态位的关键调节因子?
Am J Physiol Gastrointest Liver Physiol. 2017 Oct 1;313(4):G285-G299. doi: 10.1152/ajpgi.00073.2017. Epub 2017 Jul 6.
10
DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.双皮质素样激酶1(DCLK1)在结直肠癌中表达上调,并与转移和预后相关。
J Cancer Res Clin Oncol. 2016 Oct;142(10):2131-40. doi: 10.1007/s00432-016-2218-0. Epub 2016 Aug 12.

本文引用的文献

1
Dclk1 distinguishes between tumor and normal stem cells in the intestine.Dclk1 区分肠道中的肿瘤和正常干细胞。
Nat Genet. 2013 Jan;45(1):98-103. doi: 10.1038/ng.2481. Epub 2012 Dec 2.
2
Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27.缺氧和血清耗竭条件下通过降低 PP2A 活性和激活 p38-MAPKAPK2-Hsp27 促进肿瘤干细胞存活。
PLoS One. 2012;7(11):e49605. doi: 10.1371/journal.pone.0049605. Epub 2012 Nov 20.
3
Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue.DCAMKL-1 的免疫定位,一种假定的肠道干细胞标志物,在正常结肠组织中。
Pathol Res Pract. 2012 Aug 15;208(8):475-9. doi: 10.1016/j.prp.2012.05.015. Epub 2012 Jun 30.
4
DCLK1 immunoreactivity in colorectal neoplasia.结直肠肿瘤中的双皮质素样激酶1免疫反应性
Clin Exp Gastroenterol. 2012;5:35-42. doi: 10.2147/CEG.S30281. Epub 2012 Apr 11.
5
Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts.在细胞培养和鼠肿瘤异种移植中丙型肝炎病毒诱导的癌症干细胞样特征。
J Virol. 2011 Dec;85(23):12292-303. doi: 10.1128/JVI.05920-11. Epub 2011 Sep 21.
6
Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism.基于纳米颗粒的 siDCAMKL-1 递呈通过 Notch-1 依赖机制增加 microRNA-144 并抑制结直肠癌细胞生长。
J Nanobiotechnology. 2011 Sep 19;9:40. doi: 10.1186/1477-3155-9-40.
7
Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma.鉴定巴雷特食管和食管腺癌中的肠干细胞标志物双皮质素和钙调蛋白激酶样-1。
J Gastroenterol Hepatol. 2012 Apr;27(4):773-80. doi: 10.1111/j.1440-1746.2011.06928.x.
8
Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice.长期暴露于低氧环境可抑制大鼠和小鼠肺癌的肿瘤进展。
BMC Cancer. 2011 Aug 3;11:331. doi: 10.1186/1471-2407-11-331.
9
Gastric tuft cells express DCLK1 and are expanded in hyperplasia.胃簇细胞表达 DCLK1 并在增生中扩增。
Histochem Cell Biol. 2011 Aug;136(2):191-204. doi: 10.1007/s00418-011-0831-1. Epub 2011 Jun 18.
10
Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines.肝癌细胞系中具有癌症干细胞特性的球体形成细胞亚群。
BMC Gastroenterol. 2011 Jun 14;11:71. doi: 10.1186/1471-230X-11-71.

双皮质醇激酶 1 在人结肠癌细胞系中表现出癌症干细胞样特征。

Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line.

机构信息

Department of Surgery, Tulane University, New Orleans, LA, United States 70112; ; University of Mississippi Cancer Institute, Jackson, MS, United States 39216.

出版信息

Chin J Cancer Res. 2013 Apr;25(2):134-42. doi: 10.3978/j.issn.1000-9604.2013.03.02.

DOI:10.3978/j.issn.1000-9604.2013.03.02
PMID:23592893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3626979/
Abstract

OBJECTIVE

Colon cancer stem cells (CSCs) are implicated in colorectal cancer carcinogenesis, metastasis, and therapeutic resistance. The identification of these cells could help to develop novel therapeutic strategies. Doublecortin-like kinase 1 (DCLK1) has been viewed as a marker for gastrointestinal stem cells that fuel the self-renewal process, however others view them as a marker of Tuft cells or as an enteroendocrine subtype. The purpose of this study was to use a colon cancer cell line to identify and characterize the stem-like characteristics of the DCLK1+ cell population.

METHODS

To enrich stem-like cells, HCT116 cells (derived from colon adenocarcinomas) were cultured using serum-free media to form spheres under both normal oxygen and hypoxia condition. DCLK1 transcript expression in the adherent parental cells and spheroids was quantified using quantitative real time reverse transcription- polymerase chain reaction [(q)RT-PCR]. DCLK1 protein expression was determined using flow cytometry. Self-renewal capability from adherent parental cells and spheroids was determined using extreme limiting dilution analysis (ELDA).

RESULTS

Under both normal oxygen and hypoxia condition, the adherent parental cells were composed of cells that express low levels of DCLK1. However, spheroids exhibited an increased frequency of cells expressing DCLK1 on both mRNA and protein levels. Cells derived from spheroids also possess stronger self-renewal capability.

CONCLUSIONS

The higher fraction of DCLK1+ cells exhibited by spheroids and hypoxia reflects the stem-like characteristics of these cells. DCLK1 may represent an ideal marker to study and develop effective strategies to overcome chemo-resistance and relapse of colon cancer.

摘要

目的

结肠癌细胞(CSCs)被认为参与了结直肠癌的发生、转移和治疗耐药性。这些细胞的鉴定可能有助于开发新的治疗策略。双皮质素样激酶 1(DCLK1)被认为是胃肠道干细胞的标志物,这些干细胞为自我更新过程提供动力,然而,其他人认为它们是 Tuft 细胞的标志物,或作为肠内分泌亚型的标志物。本研究的目的是使用结肠癌细胞系鉴定和表征 DCLK1+细胞群体的类干细胞特征。

方法

为了富集类干细胞,HCT116 细胞(源自结肠腺癌)在无血清培养基中培养,在正常氧和低氧条件下形成球体。使用实时定量逆转录聚合酶链反应(qRT-PCR)定量测定贴壁亲本细胞和球体中 DCLK1 转录物的表达。使用流式细胞术测定 DCLK1 蛋白表达。使用极端极限稀释分析(ELDA)从贴壁亲本细胞和球体确定自我更新能力。

结果

在正常氧和低氧条件下,贴壁亲本细胞由表达低水平 DCLK1 的细胞组成。然而,球体在 mRNA 和蛋白水平上均表现出 DCLK1 表达增加的频率。源自球体的细胞也具有更强的自我更新能力。

结论

球体和低氧条件下 DCLK1+细胞的较高比例反映了这些细胞的类干细胞特征。DCLK1 可能代表研究和开发有效策略以克服结肠癌化疗耐药性和复发的理想标志物。